{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:47:28Z","timestamp":1770043648758,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2017R1C1B2004597"],"award-info":[{"award-number":["NRF-2017R1C1B2004597"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The epidemiological features of Waldenstr\u00f6m macroglobulinemia (WM) have seldom been investigated at a national level, particularly in East Asia. The goal of our study is to present the incidence, prevalence, mortality, survival with competing risks, and causes of death of patients with WM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We used a national population-based database, operated by the Health Insurance Review and Assessment Service of the Korean government. This data includes information on all WM patients diagnosed according to uniform criteria, between 2003 and 2016.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The total number of patients newly diagnosed with WM during the study period was 427, with a male-to-female ratio of 3.2:1. The incidence increased from 0.03 to 0.10 per 10<jats:sup>5<\/jats:sup> between 2003 and 2016, and the prevalence was 0.42 per 10<jats:sup>5<\/jats:sup> in 2016. A total of 217 patients with WM died during the study period (standardized mortality ratio\u2009=\u20097.57), and the overall survival (OS) of WM patients was 47.5%. On multivariate analysis, older age was associated with worse OS (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.0001). WM was the most common cause of death (<jats:italic>n<\/jats:italic>\u2009=\u2009102, 48.6%), followed by other malignant neoplasms (<jats:italic>n<\/jats:italic>\u2009=\u200982, 39.0%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The national incidence of WM in Korea, a racially homogeneous country in Asia, was lower than that in previous reports from other countries, reflecting ethnic disparities. However, the incidence increased, and mortality was the highest ever reported. The main cause of death was WM in itself. This study reflects the need for greater awareness of WM, particularly in Asian countries.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07120-9","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T06:14:56Z","timestamp":1593756896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Incidence, prevalence, mortality, and causes of death in Waldenstr\u00f6m macroglobulinemia: a nationwide, population-based cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Seri","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seom Gim","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5974-6884","authenticated-orcid":false,"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"7120_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110\u20135..","journal-title":"Semin Oncol"},{"key":"7120_CR2","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3109\/10428194.2012.656103","volume":"53","author":"J Sekhar","year":"2012","unstructured":"Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D. Waldenstr\u00f6m macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma. 2012;53:1625\u20136.","journal-title":"Leuk Lymphoma"},{"key":"7120_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clml.2017.02.028","volume":"17","author":"S Yun","year":"2017","unstructured":"Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L, Baz RC, Anwer F. Waldenstrom Macroglobulinemia: review of pathogenesis and management. Clin Lymphoma Myeloma Leuk. 2017;17:252\u201362.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7120_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/bjh.13264","volume":"169","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenstr\u00f6m macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Br J Haematol. 2015;169:81\u20139.","journal-title":"Br J Haematol"},{"key":"7120_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/1471-2407-12-503","volume":"12","author":"YC Liu","year":"2012","unstructured":"Liu YC, Yang YH, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Chang PY, et al. Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - a nationwide population-based matched-control study in Taiwan. BMC Cancer. 2012;12:503.","journal-title":"BMC Cancer"},{"key":"7120_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/1471-2407-11-255","volume":"11","author":"J Ma","year":"2011","unstructured":"Ma J, Wang S, Zhao M, Deng XS, Lee CK, Yu XD, Liu B. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer. 2011;11:255.","journal-title":"BMC Cancer"},{"key":"7120_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ajh.23351","volume":"88","author":"SY Kristinsson","year":"2013","unstructured":"Kristinsson SY, Eloranta S, Dickman PW, Andersson TM-L, Turesson I, Landgren O, Bj\u00f6rkholm M. Patterns of survival in lymphoplasmacytic lymphoma\/waldenstr\u00f6m macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol. 2013;88:60\u20135.","journal-title":"Am J Hematol"},{"key":"7120_CR8","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","volume":"123","author":"JJ Castillo","year":"2014","unstructured":"Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenstrom macroglobulinemia: an analysis of the surveillance, Epidemiology and End Results database. Blood. 2014;123:3999\u20134000.","journal-title":"Blood"},{"key":"7120_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000360992","volume":"86","author":"S Ailawadhi","year":"2014","unstructured":"Ailawadhi S, Kardosh A, Yang D, Cozen W, Patel G, Alamgir MA, Chanan-Khan AA. Outcome disparities among ethnic subgroups of Waldenstr\u00f6m's Macroglobulinemia: a population-based study. Oncology. 2014;86:253\u201362.","journal-title":"Oncology."},{"key":"7120_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ajh.22027","volume":"86","author":"E Kastritis","year":"2011","unstructured":"Kastritis E, Kyrtsonis MC, Hatjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Michael M, Sioni A, Kartasis Z, et al. No significant improvement in the outcome of patients with Waldenstr\u00f6m's macroglobulinemia treated over the last 25 years. Am J Hematol. 2011;86:479\u201383.","journal-title":"Am J Hematol"},{"key":"7120_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.leukres.2007.02.002","volume":"32","author":"KJ Phekoo","year":"2008","unstructured":"Phekoo KJ, Jack RH, Davies E, M\u00f8ller H, Schey SA. The incidence and survival of Waldenstr\u00f6m's Macroglobulinaemia in south East England. Leuk Res. 2008;32:55\u20139.","journal-title":"Leuk Res"},{"key":"7120_CR12","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1002\/cncr.26627","volume":"118","author":"H Wang","year":"2012","unstructured":"Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, Kwak L, Rustveld L, Du XL, Wang M. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118:3793\u2013800.","journal-title":"Cancer."},{"issue":"10","key":"7120_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10552-008-9184-z","volume":"19","author":"JD Carreon","year":"2008","unstructured":"Carreon JD, Morton LM, Devesa SS, Clarke CA, Gomez SL, Glaser SL, Sakoda LC, Linet MS, Wang SS. Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996-2004. Cancer Causes Control. 2008;19(10):1171\u201381.","journal-title":"Cancer Causes Control"},{"key":"7120_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265\u201376.","journal-title":"Blood."},{"key":"7120_CR15","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","volume":"82","author":"M Iwanaga","year":"2007","unstructured":"Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal Gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clinic Proceedings. 2007;82:1474\u20139.","journal-title":"Mayo Clinic Proceedings"},{"key":"7120_CR16","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ. Prevalence of monoclonal Gammopathy of undetermined significance. N Engl J Med. 2006;354:1362\u20139.","journal-title":"N Engl J Med"},{"key":"7120_CR17","doi-asserted-by":"publisher","unstructured":"Kristinsson SY, Bjo M, Goldin LR, Mcmaster ML, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoma\/Waldenstr\u00f6m macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112:3052\u20136. https:\/\/doi.org\/10.1182\/blood-2008-06-162768.","DOI":"10.1182\/blood-2008-06-162768"},{"key":"7120_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000335618","volume":"127","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY, Goldin LR, Turesson I, Bj\u00f6rkholm M, Landgren O. Familial aggregation of lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia with solid tumors and myeloid malignancies. Acta Haematol. 2012;127:173\u20137.","journal-title":"Acta Haematol"},{"key":"7120_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/jnci\/djq043","volume":"102","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Koshiol J, Bj\u00f6rkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or waldenstr\u00f6m macroglobulinemia. J Natl Cancer Inst. 2010;102:557\u201367.","journal-title":"J Natl Cancer Inst"},{"key":"7120_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/ijc.23229","volume":"122","author":"ML McMaster","year":"2008","unstructured":"McMaster ML, Csako G. Protein electrophoresis, immunoelectrophoresis and immunofixation electrophoresis as predictors for high-risk phenotype in familial Waldenstr\u00f6m macroglobulinemia. Int J Cancer. 2008;122:1183\u20138.","journal-title":"Int J Cancer"},{"key":"7120_CR21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ijc.29478","volume":"137","author":"F Neumann","year":"2015","unstructured":"Neumann F, Pfreundschuh M, Preuss KD, Schormann C, Zwick C, Murawski N, Kubuschok B. CD4+ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenstr\u00f6m's macroglobulinemia. Int J Cancer. 2015;137:1076\u201384.","journal-title":"Int J Cancer"},{"key":"7120_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.mayocp.2018.02.011","volume":"93","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, McPhail ED, Therneau TM, Dispenzieri A, Kumar S, Kapoor P, Cerhan JR, Rajkumar SV. Fifty-year incidence of Waldenstr\u00f6m Macroglobulinemia in Olmsted County, Minnesota, from 1961 through 2010: a population-based study with complete case capture and Hematopathologic review. Mayo Clin Proc. 2018;93:739\u201346.","journal-title":"Mayo Clin Proc"},{"key":"7120_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ijc.28343","volume":"134","author":"M Iwanaga","year":"2014","unstructured":"Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y, Matsuo K, Matsuda T, Sobue T. Incidence of lymphoplasmacytic lymphoma\/Waldenstr\u00f6m's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. Int J Cancer. 2014;134:174\u201380.","journal-title":"Int J Cancer"},{"key":"7120_CR24","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","volume":"82","author":"FD Groves","year":"1998","unstructured":"Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF. Waldenstr\u00f6m's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998;82:1078\u201381.","journal-title":"Cancer."},{"key":"7120_CR25","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.V82.10.3148.3148","volume":"82","author":"LJ Herrinton","year":"1993","unstructured":"Herrinton LJ, Weiss NS. Incidence of Waldenstrom ' s macroglobulinemia incidence of Waldenstrom \u2019 s Macroglobulinemia. Blood. 1993;82:3148\u201350.","journal-title":"Blood."},{"key":"7120_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1586\/ehm.11.82","volume":"5","author":"P Morel","year":"2012","unstructured":"Morel P, Merlini G. Risk stratification in Waldenstr\u00f6m macroglobulinemia. Expert Rev Hematol. 2012;5:187\u201399.","journal-title":"Expert Rev Hematol"},{"key":"7120_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00277-012-1545-8","volume":"91","author":"M Hensel","year":"2012","unstructured":"Hensel M, Brust J, Pl\u00f6ger C, Schuster D, Memmer ML, Franz-Werner J, Feustel HP, Karcher A, Fuxius S, Mosthaf FA, et al. Excellent long-term survival of 170 patients with Waldenstr\u00f6m's macroglobulinemia treated in private oncology practices and a university hospital. Ann Hematol. 2012;91:1923\u20138.","journal-title":"Ann Hematol"},{"key":"7120_CR28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00277-001-0385-8","volume":"80","author":"MC Kyrtsonis","year":"2001","unstructured":"Kyrtsonis MC, Vassilakopoulos T, Angelopoulou M, Siakantaris M, Kontopidou F, Dimopoulou M, Boussiotis V, Gribabis D, Konstantopoulos K, Vaiopoulos G, et al. Waldenstr\u00f6m macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol. 2001;80:722\u20137.","journal-title":"Ann Hematol"},{"key":"7120_CR29","doi-asserted-by":"crossref","unstructured":"Lee HS, Kim K, Yoon DH, Kim JS, Bang S-M, Lee J-O, Eom HS, Lee H, Kim I, Lee WS, et al. Clinical factors associated with response or survival after chemotherapy in patients with Waldenstr\u00f6m macroglobulinemia in Korea. Biomed Res Int. 2014;2014.","DOI":"10.1155\/2014\/253243"},{"key":"7120_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","volume":"126","author":"SP Treon","year":"2015","unstructured":"Treon SP. How I treat Waldenstrome Macroglobulinemia. Blood. 2015;126:721\u201333.","journal-title":"Blood."},{"key":"7120_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1023\/A:1008350208019","volume":"10","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, Grillo-L\u00f3pez AJ. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol. 1999;10:1525\u20137.","journal-title":"Ann Oncol"},{"key":"7120_CR32","first-page":"1655","volume":"90","author":"MA Dimopoulos","year":"2005","unstructured":"Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstr\u00f6m's macroglobulinemia with bortezomib. Haematologica. 2005;90:1655\u20138.","journal-title":"Haematologica."},{"key":"7120_CR33","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1080\/10428190410001714043","volume":"45","author":"MA Gertz","year":"2004","unstructured":"Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenstr\u00f6m Macroglobulinemia (WM): an eastern cooperative oncology group study (E3A98). Leukemia Lymphoma. 2004;45:2047\u201355.","journal-title":"Leukemia Lymphoma"},{"key":"7120_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3816\/CLML.2011.n.030","volume":"11","author":"SP Treon","year":"2011","unstructured":"Treon SP, Hanzis C, Tripsas C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy P. Bendamustine therapy in patients with relapsed or refractory Waldenstr\u00f6m's Macroglobulinemia. Clin Lymphoma Myeloma Leukemia. 2011;11:133\u20135.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"7120_CR35","doi-asserted-by":"publisher","unstructured":"Oza A, Rajkumar SV. Waldenstrom macroglobulinemia: prognosis and management. 2015. https:\/\/doi.org\/10.1038\/bcj.2015.28.","DOI":"10.1038\/bcj.2015.28"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07120-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T23:31:13Z","timestamp":1625268673000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07120-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7120"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07120-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"1 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the independent Institutional Review Board of Kosin University Gospel Hospital (KUGH 2017\u201311-027) and conducted in accordance with the Declaration of Helsinki. This study was exempted from the requirement for informed patient consent because personal information was protected and kept anonymous.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"623"}}